Loading viewer...
conference
Format: PDF conference
Revance Therapeutics presented its 2024 strategic priorities and commercial update at the JP Morgan Healthcare Conference, focusing on DAXXIFY® expansion into therapeutics including cervical dystonia, RHA® dermal fillers pipeline growth, and path to positive adjusted EBITDA. The presentation covers commercialization strategy, market opportunities, and financial guidance for 2024.
investor_presentation
106 Pages
conference
116 Pages
Eramet
EPA Community Equity Resiliency Regional Roadshow Kansas City
conferenceconference
63 Pages
U.S. Environmental Protection Agency
Geopolitical Shocks Inflation Federal Reserve 2024
conferenceconference
16 Pages
Federal Reserve Board